MethylScan HCC

What is MethylScan™ HCC?                                        

EarlyDx’s MethylScan™ test analyzes DNA methylation patterns in cell-free DNA (cfDNA) circulating in the bloodstream, offering an assessment of liver health from a single blood
draw. Using deep learning, MethylScan™ HCC can detect hepatocellular carcinoma at early stages in the at-risk population with high sensitivity and specificity.

 

Why It Matters?

• Standard HCC surveillance (ultrasound + AFP) misses approximately 37% of early tumors.
• MethylScan™ HCC adds sensitivity by tracking tumor-specific cfDNA methylation patterns.

Who Should Be Monitored?

At-risk individuals include those with:

• Cirrhosis (from hepatitis B/C, NASH, alcohol)
• Chronic hepatitis B (even without cirrhosis)

Guidelines recommend semi-annual AFP blood tests and ultrasound. Now, you can add MethylScan™ HCC to improve early detection.

 

Key Features

• Highly sensitive & specific cfDNA methylation assay
• Non-invasive blood test, ideal for routine surveillance
• Commercially available: PLA code 0565U

MethylScan™ HCC is ideal for hepatologists and high-risk patient management programs.